All News
Colchicine Approval Took a Huge Toll on CMS
d
Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.
Read Article
How are RA patients doing using telemedicine/virtual care?
Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?
Read Article
#BestACR20Tweets
RT @MeralElRamahiMD :Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @ElaineHusniMD https://t.co/tCAbgYi3h0 https://t.co/AoEOJd3pQh
Links:
Dr. John Cush RheumNow ( View Tweet)
How COVID Changed Work: Drs. Rachel Tate, Cassie Calabrese and Mary Hinojos Mamut #ACR20
https://t.co/jyM8NPicZF https://t.co/6zA7Kmgzwi
Links:
Dr. John Cush RheumNow ( View Tweet)
Measuring Disease Activity in Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) looks at several abstracts that focus on disease activity measurement in psoriatic arthritis presented at the #ACR20 meeting.
https://t.co/Tu58NDbc51 https://t.co/RGwON4gu7w
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Treatment recommendations for Hepatitis B - highest risk is for RTX for reactivation! @RheumNow. https://t.co/JvYm9Ii6PV https://t.co/qjXBuzUug6
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR has released 2 free powerpoint slide decks featuring select RA and SLE abstracts from #ACR20 (a 3rd late-breaking slide deck is yet to come!). Download here>> https://t.co/CiNH0xfs7J
Links:
Dr. John Cush RheumNow ( View Tweet)
Cytokine Storm | NEJM https://t.co/sNNKtdPYw8 #cyokinestorm #inflammasomopathy nice review underlying a number of our “auto inflammatory “ funny seronegs with gut rash and other odd features?
Peter Nash drpnash ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: MTX is conditionally recommended with NORMAL LFTs and no advanced fibrosis. Role of HCQ for NALFD has been suggested at ACR, but not enough for mod-high disease activity @RheumNow. https://t.co/XswkhT1f66 https://t.co/bdngrnY9hc
Links:
Dr. John Cush RheumNow ( View Tweet)
Revisit #ACR20 with our RheumNow podcast.
https://t.co/ondNw0G6Pu https://t.co/nauqdGp8fR
Links:
Dr. John Cush RheumNow ( View Tweet)
Worth the read!
My Experience as a COVID19 Vaccine Trial Participant by Dr. Kathryn Dao ( @KDAO2011)
https://t.co/ILfXLUL8IZ https://t.co/7parTGPllu
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Switching or adding a DMARD in pts w/ mod-high dz RA activity ; hx of previous serious infection w/in the past 12 mos as opposed to starting/increasing GCs is conditionally recommended per draft recs of new ACR RA treatment guidelines.
Dr. John Cush RheumNow ( View Tweet)
Prothrombotic Antiphospholipid Antibodies in COVID-19: Dr. David Liew ( @drdavidliew) abstract #0429 at the #ACR20.
https://t.co/5xjThWuLa6 https://t.co/Aezlfqle06
Links:
Dr. John Cush RheumNow ( View Tweet)
New Treatments in Axial Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints) discuses two abstracts presented at the #ACR20 annual meeting.
https://t.co/bh7l6C8p7P https://t.co/RN60iWCmet
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @DrPujaMehta1 #ACR20 Abstr#L06 https://t.co/ynWbguXXzR
Dr. John Cush RheumNow ( View Tweet)
IVIg in Dermatomyositis: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0995 presented at #ACR20.
https://t.co/PKYATqUh0d
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow
Dr. John Cush RheumNow ( View Tweet)
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20
https://t.co/WjcBPay86P https://t.co/JnUVss0FDK
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Patient-physician discordance seen in ~30% RA patients starting #DMARDs
- ↑Patient-reported pain; functional impairment assoc. w/ discordance
- Patient-centric treatment discussions needed to reduce discordance
Abs#1978
https://t.co/uTJehn5Qs5 https://t.co/289d3VsE22
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA
Phase 3 RCT
⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA
*⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior
*⃣Similar VTE in all arms
#ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
